DOI: 10.6084/m9.figshare.29166849
title: Exploring study dropout in drug trials for adults with PTSD: insights from a conventional and individual participant data meta-analysis

description: <b>Background:</b> Dropout rates and factors contributing to dropout in drug and placebo groups in pharmacotherapy trials for posttraumatic stress disorder (PTSD) are not well understood. <b>Objective:</b> This study aimed to examine differences in all-cause study dropouts between drug and placebo groups, using conventional meta-analysis and an exploratory predictor analysis of individual participant data from three trials. <b>Method:</b> We included randomized controlled trials (RCTs) of adults with PTSD, comparing drug monotherapy with placebo. Forty-three RCTs (<i>n</i> = 4829) were included in a conventional meta-analysis. Additionally, we conducted a small exploratory predictor analysis including participant-level data from three RCTs (<i>n</i> = 246). <b>Results:</b> In the conventional meta-analysis, study dropout was marginally lower in the drug relative to the placebo group, but the difference was not significant, RR = 0.92, 95% CI [0.83, 1.02], <i>p</i> = .099. Drug class, dosing regimen, population, study duration, or gender were not related to dropout. In the exploratory predictor analysis, study dropout did not differ significantly between drug and placebo groups <i>(p</i> = .617). In the drug group, gender was a significant predictor for dropout, with males having higher dropout rates (<i>p</i> = .046). When controlling for baseline PTSD symptom severity, gender was no longer a statistically significant predictor (<i>p</i> = .051). None of the other predictors in <i>drug, placebo, and combined</i> group analyses were significant in predicting drop-out. <b>Conclusions:</b> This study demonstrated that study dropout rates in monotherapy pharmacotherapy RCTs for PTSD do not significantly differ between drug and placebo groups. These findings underscore the need for further research to identify the factors contributing to dropout in PTSD pharmacotherapy trials and to develop tailored treatment adherence strategies. Additionally, they highlight the importance of pooling participant-level data to facilitate more comprehensive and granular analyses in future research. This study found no significant differences in dropout rates between drug and placebo groups in PTSD pharmacotherapy trials, with an overall high dropout rate of 28%, highlighting a major challenge in these trials.Initial analyses indicated that males were at a higher risk of dropping out of drug treatment compared with females, though this effect was not significant after controlling for PTSD severity. This suggests a complex interaction between gender, PTSD severity, and dropout rates.The study underscores the importance of standardized protocols for reporting reasons for discontinuation in clinical trials to identify precise predictors of dropout and improve the reliability and comparability of research findings. This study found no significant differences in dropout rates between drug and placebo groups in PTSD pharmacotherapy trials, with an overall high dropout rate of 28%, highlighting a major challenge in these trials. Initial analyses indicated that males were at a higher risk of dropping out of drug treatment compared with females, though this effect was not significant after controlling for PTSD severity. This suggests a complex interaction between gender, PTSD severity, and dropout rates. The study underscores the importance of standardized protocols for reporting reasons for discontinuation in clinical trials to identify precise predictors of dropout and improve the reliability and comparability of research findings.